NCT01653366

Brief Summary

This study is a randomized prospective clinical trial of women with metastatic breast cancer. The purpose of the study is to test if an intervention of regular physical activity review and physical activity goal setting will allow the subjects to achieve a moderate increase in physical activity of 6,000 steps per week. The physical activity review will consist of weekly telephone call to inquire about symptoms and to set physical activity goals. The study will also look to see if the goal setting intervention will affect the time to progression, change in BMI, and quality of life. Quality of life will be measured by answers to questionnaires provided to subjects at regular intervals during the course of the study. Finally, the study will examine the impact of physical activity on expression of tumor molecular molecules, insulin levels, and estradiol levels. Through an intervention of regular physical activity review and goal setting, the investigators hypothesize that a moderate increase in level of physical activity of 6000 steps per week or more can be obtained by patients with metastatic breast cancer who receive a goal setting intervention. The investigators propose that those who are able to achieve and maintain greater than or equal to 22500 steps per week will demonstrate biologic and molecular differences compared to those who are not able to achieve that level of physical activity. The investigators expect that people who are more active will have longer to progression.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 19, 2012

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 31, 2012

Completed
4 months until next milestone

Study Start

First participant enrolled

December 1, 2012

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

August 16, 2016

Status Verified

June 1, 2012

Enrollment Period

3.1 years

First QC Date

July 19, 2012

Last Update Submit

August 15, 2016

Conditions

Keywords

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • Change in physical activity as a result of a goal setting intervention using pedometer data and exercise logs.

    To increase physical activity levels by at least 6000 steps/wk over 6 months using a goal setting intervention

    Baseline, 2 month, 3 month, 4 month, 5 month, 6 months

Secondary Outcomes (7)

  • Secondary objectives: Time to progression

    baseline, 6 months

  • Change in Body Mass Index (BMI)

    Baseline, 2 month, 3 month, 4 month, 5 month, 6 months

  • Health related quality of life

    baseline, 6 months

  • Correlative Science outcomes in peripheral blood

    baseline, 6 months

  • Correlative science outcomes in tissue biopsies

    baseline, 6 months

  • +2 more secondary outcomes

Study Arms (2)

Arm A-Pedometer and Goal setting

EXPERIMENTAL

Physical Activity Goal Setting Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log.

Behavioral: Physical Activity Goal Setting

ARM B

NO INTERVENTION

Patients receive standard physical activity recommendations and follow up.

Interventions

Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the "Exercise and Breast Cancer" digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them.

Arm A-Pedometer and Goal setting

Eligibility Criteria

Age18 Years - 99 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with measurable per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 and biopsy-able (as determined by Co-Investigator John Gemery, MD) metastatic carcinoma of the breast.
  • Physically able to undertake a moderate physical activity program.
  • Greater than 4 weeks from any radiation treatments for metastatic disease.
  • standard of care biopsy must occur within 30 days of registration.
  • Able to follow directions and fill out questionnaires and physical activity diaries in English.
  • Willing to consent to biopsies and be randomly assigned to one of two study arms which may or may not include physical activity goal setting.
  • Consents to be contacted via phone or internet (see Appendix K).
  • No to all questions on Physical Activity Readiness Questionnaire (see appendix A) or approved by primary oncologist or other care provider provider for participation.
  • Hb \>10 without transfusion, liver function tests less than 3 times upper limits of normal, normal thyroid-stimulating hormone (TSH), absolute neutrophil count (ANC) \>1500.
  • Karnofsky performance status ≥ 80%
  • Previous Physical Therapy consultation and treatments acceptable.
  • Participation in other trials acceptable.
  • CNS disease that is treated and stable by MRI for at least 6 months

You may not qualify if:

  • Patients less than 18 years of age.
  • Patients unable to give informed consent indicating they are aware of the investigational nature of this treatment, prior to entry into the study.
  • Pregnant or nursing women.
  • Patients with any untreated (CNS) disease.
  • Patients with other active cancers requiring treatment.
  • Patients with clotting or bleeding disorder precluding biopsy.
  • Patients with significant cardiovascular disease, including uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months or serious cardiac arrhythmias will be excluded.
  • Current use of supplements containing conjugated linoleic acid, or use within the 30 days preceding registration.
  • Persons with a known diagnosis of diabetes are not eligible. Prior use of metformin allowable if previously enrolled on MA.32 trial as part of their adjuvant therapy for early stage breast cancer.
  • Persons of male gender.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mary Chamberlin, MD

    Dartmouth-Hitchcock Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2012

First Posted

July 31, 2012

Study Start

December 1, 2012

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

August 16, 2016

Record last verified: 2012-06

Locations